SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Active:	No
Cancer Type:	Lung Cancer Melanoma	NCT ID:	NCT04291079
Trial Phases:	Phase I	Protocol IDs:	SRK-181-001 (primary) NCI-2020-05381
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Scholar Rock, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04291079

Summary

This is a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and
dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD), and efficacy of SRK-181 administered alone and in combination with
anti-PD-(L)1 therapy in adult patients with locally advanced or metastatic solid tumors.
The study is divided into 3 treatment parts (Part A1, Part A2, and Part B) and a
Long-Term Extension Phase (LTEP).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.